English Deutsch 中文
  • Innovative Solutions
  • Expert Support and Knowledge
  • Reliable Cooperation
Menu Deutsch 中文

Shenogen Pharma of Beijing Raises $20 Million in C Round

Aug. 5, 2013

Shenogen Pharma of Beijing raised $20 million in a series C funding round, which the company will use to support a Phase II trial of its lead drug candidate, icaritin - a small molecule drug that targets the estrogen receptor alpha 36. The trial will enroll patients with hepatocellular cancer. The funding was led by Legend Capital and Qiming Weichuang Venture Capital. The investors also received warrants to buy an additional $10 million in shares.